Figure 4.

TXL protects HCMECs against EndMT induced by hypoxia. (a) Immunofluorescence staining showed the endothelial markers vWF and mesenchymal markers Vimentin in the control group, treated with hypoxia (1% O2) for 3 days and cotreated with TXL (600 ug·ml⁻¹) and hypoxia (1% O2) for 3 days. Nuclear staining with DAPI (blue), scale bar: 50μm. (b) Effects of TXL on protein expression of CD31, VE-cadherin, α-SMA, and FSP-1 in vitro were determined by Western blotting analysis. (b1)–(b4) showed corresponding column chart. n=3, ∗∗P<0.01 vs. control group; ^#P<0.05 ^## P<0.01 vs. hypoxia group.